Dr. Callander Discusses Combinations in Multiple Myeloma

Natalie S. Callander, MD
Published: Wednesday, Oct 11, 2017



Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Both the POLLUX and CASTOR trials showed high response rates with the use of triplets that involved daratumumab (Darzalex), says Callander.

Callander adds that combinations with elotuzumab (Empliciti), as well as ixazomib (Ninlaro), have shown excellent results as well.
 
SELECTED
LANGUAGE


Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Both the POLLUX and CASTOR trials showed high response rates with the use of triplets that involved daratumumab (Darzalex), says Callander.

Callander adds that combinations with elotuzumab (Empliciti), as well as ixazomib (Ninlaro), have shown excellent results as well.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x